Trials / Unknown
UnknownNCT03270007
Research of Intensive Treatment in Hormone Receptor<10% and Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer Patients With Positive Lymph Node Residual Disease After Neoadjuvant Chemotherapy
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 304 (estimated)
- Sponsor
- Tao OUYANG · Academic / Other
- Sex
- Female
- Age
- 18 Years – 66 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase IV, single-center, prospective, open-label, randomized,controlled study
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Vinorelbine | different from primary chemotherapy(containing anthracycline or paclitaxel) |
Timeline
- Start date
- 2017-11-10
- Primary completion
- 2024-06-30
- Completion
- 2024-12-31
- First posted
- 2017-09-01
- Last updated
- 2020-10-28
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03270007. Inclusion in this directory is not an endorsement.